Integro Theranostics announces positive Phase 1b clinical trial data, advancing CXL into Phase II Study
Lung cancer surgery study results for proprietary tumor-targeting agent, CXL (formerly known as LS301), shows promising preliminary safety and efficacy for IMI. SAINT LOUIS, MO, UNITED STATES, November 17, 2025 /EINPresswire.com/ -- Positive …